Did you know that 60 percent of pharmaceutical production is outsourced? As drug development costs rise, CDMOs have become safe havens for biopharma companies by offering scalable, cost-effective, and cutting-edge technology solutions for drug development and manufacturing.
In March, PharmaShots Magazine is navigating the evolving Biopharma CDMO frontier by decoding trends, illustrative infographics, thought-provoking articles,…
Where disruption meets direction
In the past year, pharma has witnessed disruption in the external environment and internal restructure. We’ve reorganized for patients and customers – but it’s one thing to change a job title, another to transform outcomes.
But how do you plan for the next wave of change across technology, regulations and expectations?
For over…
Shots:
Driven by an endless pursuit of innovation, the biopharma industry is working tirelessly to bring new-age therapies to patients with serious health conditions and lifestyle-influenced diseases
In 2023, the global prescription drug market size was valued at $1162.61B and is anticipated to reach $2151.63B by 2032 registering a CAGR of 7.1 %. Keytruda ranks 1st…
In the second reprise of our Complimentary Exclusive Video Interview, we had the pleasure to speak with Nick Kadysh, the Founding CEO and President of PharmAla Biotech. Our complimentary exclusive video interview is an initiative to voice the global biopharma leaders by offering them a platform to shed light on the developments in the healthcare…
Shots:
Backed with an evergreen investment strategy, Invus makes investments across several company stages ranging from early growth to turnarounds
In 2023, Invus participated in 6 investment rounds in around 29 companies focusing on biopharma, manufacturing & services, and devices
For a curated report on a specific investor or venture capital, reach out to us…
Shots:
Vaccines play an instrumental role in curbing infectious diseases by generating antibodies against antigens and creating a memory to defeat them. Several biopharma companies are steadfastly working to deliver vaccines against infectious and vaccine-preventable diseases around the world
In 2024, the global vaccine market is estimated to be around $78B and is expected to…
Shots:
Sticking to M&A and licensing agreements can be really challenging, especially when dealing with stringent antitrust laws and evolving regulatory challenges. In such adverse scenarios, the rational and right step seems to be nullifying the existing deals.
In 2023, the termination of the deal between Janssen and Arrowhead remained the talk of the town…
Shots:
Clinical-stage biopharma companies are in constant need of funding and the best way to pull in money in such dire situations is by going public. 2023 had been a great year for Wall Streets across the globe with continuous announcements of IPOs
Kenvue by bagging $4.37B upon completion of its IPO ranked first in…
Shots:
In this reprise, we feature Qiming Venture Partners again, based on the investments in 2023. With more than 600 investments to date, Qiming boasts a strong portfolio of companies involved in Technology & Consumer and Healthcare
In 2023, Qiming closed 38 funding rounds comprising 11 in the first quarter, 10 in the second, 11…
Shots:
The EMA approved 5 BLA and 8 New Chemical Entities in February 2024, leading to treatments for patients and advances in the healthcare industry
In February 2024, the major highlighted drugs were Reblozyl to treat Transfusion-Dependent Anemia and Velsipity for the treatment of Severely Active Ulcerative Colitis
PharmaShots has compiled a list of a total…

